Literature DB >> 27400224

A Study of Aβ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls.

Armand Savioz1, Panteleimon Giannakopoulos, François R Herrmann, William L Klein, Enikö Kövari, Constantin Bouras, Ezio Giacobini.   

Abstract

BACKGROUND/AIMS: Investigations of Aβ oligomers in neuropathologically confirmed Alzheimer's disease (AD) are still scarce. We report neurohistopathological and biochemical analyses using antibodies against tau and amyloid β (Aβ) pathology.
METHODS: Thirty elderly AD patients and 43 age-matched controls with or without deposition of amyloid plaques (AP) were analyzed by immunohistochemistry. In 21 cases with available fresh tissue, Western blots were also performed. Neuropathological analysis included quantitative assessment of neurofibrillary tangles (NFT), AP and Aβ oligomer densities in the mesial temporal cortex (TC).
RESULTS: NFT, fibrillar amyloid and Aβ oligomeric deposit densities were significantly higher in AD patients than in controls. There was no relationship between oligomeric Aβ densities and Braak NFT staging scores. Furthermore, Aβ oligomer expression was closely correlated with Aβ plaques in the TC. By Western blot, Aβ oligomers were observed in AD patients, in plaque-free controls, in 1 'tangle-only AD' case, as well as in the cerebellum. A band near 55 kDa was the only Western blot signal that was significantly increased in the TC of AD patients compared to controls as well as less expressed in the cerebellum.
CONCLUSION: These results suggest that a putative dodecamer, near 55 kDa, may contribute to AD vulnerability of the TC.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27400224     DOI: 10.1159/000446283

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  7 in total

1.  A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers.

Authors:  Adriano Sebollela; Erika N Cline; Izolda Popova; Kevin Luo; Xiaoxia Sun; Jay Ahn; Milena A Barcelos; Vanessa N Bezerra; Natalia M Lyra E Silva; Jason Patel; Nathalia R Pinheiro; Lei A Qin; Josette M Kamel; Anthea Weng; Nadia DiNunno; Adrian M Bebenek; Pauline T Velasco; Kirsten L Viola; Pascale N Lacor; Sergio T Ferreira; William L Klein
Journal:  J Neurochem       Date:  2017-08-02       Impact factor: 5.372

2.  The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation.

Authors:  Fatou Amar; Mathew A Sherman; Travis Rush; Megan Larson; Gabriel Boyle; Liu Chang; Jürgen Götz; Alain Buisson; Sylvain E Lesné
Journal:  Sci Signal       Date:  2017-05-09       Impact factor: 8.192

Review 3.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.

Authors:  Erika N Cline; Maíra Assunção Bicca; Kirsten L Viola; William L Klein
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Nanoscale structure of amyloid-β plaques in Alzheimer's disease.

Authors:  Marta Querol-Vilaseca; Martí Colom-Cadena; Jordi Pegueroles; Raúl Nuñez-Llaves; Joan Luque-Cabecerans; Laia Muñoz-Llahuna; Jordi Andilla; Olivia Belbin; Tara L Spires-Jones; Ellen Gelpi; Jordi Clarimon; Pablo Loza-Alvarez; Juan Fortea; Alberto Lleó
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

5.  ApoE-fragment/Aβ heteromers in the brain of patients with Alzheimer's disease.

Authors:  Amandine Mouchard; Marie-Charlotte Boutonnet; Claire Mazzocco; Nathalie Biendon; Nathalie Macrez
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

Review 6.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

7.  β-amyloid expression in age-related cataract lens epithelia and the effect of β-amyloid on oxidative damage in human lens epithelial cells.

Authors:  Jie Xu; Dan Li; Tianyu Zheng; Yi Lu
Journal:  Mol Vis       Date:  2017-12-25       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.